Table 3.
Deregulated miRNAs in selected studies in EAOC.
| Reference | Effect | Experimental Design | Main Deregulated miRNAs in Patients |
|---|---|---|---|
| [100] | Promoted proliferation, migration, invasion | OCCC and adjacent non-tumor tissues | ↓ miR-424 |
| [101] | Increased cell motility, growth and colony formation | OCCC and EOC cell lines and OMA primary stromal cells | ↓ miR-381 |
| [102] | Increased cell proliferation and invasion | EOC, OCCC, OMA and control endometria tissues | ↑ miR-191 |
| [103] | Increased MET phenotype and good prognosis | HGSOC, EOC, OCCC and mucinous ovarian cancer tissues | ↓ miR-506 |
| [104] | Increased EMT phenotype | HGSOC and OSE tissues | ↑ miR-205-5p |
| EMT (miR-200s), poor PFS and OS (miR-200c -3p) | HGSOC, OCCC and OSE tissues | ↑ miR-200s, miR-182-5p ↓miR-383 |
|
| Hystology differentiatiors | OCCC and HGSOC tissues | ↑ miR-509-3-5p, miR-509-3p, miR-509-5p, miR-510 | |
| [105] | Poor overall survival | OCCC and HGSOC tissues | ↓ miR-510, miR-129-3p |
| [106] | Increased EMT phenotype | OCCC and HGSOC tissues | ↑ miR-9 |
| [107] | Down-regulation of the TSG PTEN | OCCC tissues | ↑ miR-21 |
| [108] | Increased paclitaxel chemosensitivity | OCCC cell lines | ↑ miR-29b |
| [109] | Poor prognosis | OCCC, HGSOC, mucinous ovarian cancer and control tissues | ↓ miR-29b |
| [110] | Increased apoptosis evasion | EOC, OMA and control tissues | ↑ miR-191 |
| [111] | Hystology differentiatiors | OCCC, EOC, HGSOC and mucinous ovarian cancer | ↑ miR-30a and miR-30a * |
| [112] | Poor overall survival in ovarian papillary serous carcinoma tissues | OCCC and ovarian papillary serous carcinoma tissues | ↓ miR-30a, miR-30e and miR-505 |
| [113] | Enhanced sensitivity to everolimus | OCCC and OSE cell lines | ↓ miR-100 |
↑, up-regulated levels; ↓, down-regulated levels; EOC, endometrioid ovarian cancer; OCCC, ovarian clear cell carcinoma; OSE, ovarian surface epithelium; HGSOC, high-grade serous ovarian cancer; EMT, epithelial-to-mesenchymal transition; MET, mesenchymal-to-epithelial transition. PTEN, phosphatase and tensin homologue; TSG, tumour suppressor gene; PFS, progression-free survival.